down arrow

Benitec Biopharma, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US08205P2092
USD
13.18
1.53 (13.13%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

12.4913.22

52 Week

9.4917.15
Valuation
Technical
Day's Volume

CASH

483.22 k

Shareholding (Mar 2025)

FII

9.03%

Held by 7 FIIs

DII

83.07%

Held by 10 DIIs

Promoter

0.00%

How big is Benitec Biopharma, Inc.?

22-Jun-2025

As of Jun 18, Benitec Biopharma, Inc. has a market capitalization of 405.31 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -26.49 million for the latest four quarters. As of June 2024, shareholder's funds were 47.25 million and total assets were 52.21 million.

Market Cap: As of Jun 18, Benitec Biopharma, Inc. has a market capitalization of 405.31 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters ending in March 2025, December 2024, September 2024, and June 2024, the company reported net sales of 0.00 million and a net profit of -26.49 million.<BR><BR>Balance Sheet Snapshot: As of June 2024, the company's shareholder's funds amounted to 47.25 million, while total assets were reported at 52.21 million.

Read More

What does Benitec Biopharma, Inc. do?

22-Jun-2025

Benitec Biopharma, Inc. is a clinical-stage biotechnology company focused on developing genetic medicines. As of March 2025, it has a market cap of $405.31 million and reported a net profit loss of $9 million.

Overview: <BR>Benitec Biopharma, Inc. is a clinical-stage biotechnology company focused on the development of genetic medicines within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -9 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 405.31 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.06 <BR>Return on Equity: -27.93% <BR>Price to Book: 4.15<BR><BR>Contact Details: <BR>Address: Level 14, 114 William St, MELBOURNE VIC: 3000 <BR>Tel: 61 3 86927222 <BR>Website: https://benitec.com/

Read More

Is Benitec Biopharma, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Benitec Biopharma, Inc. shows a mildly bearish trend due to daily moving averages and bearish signals from KST and Dow Theory, despite some bullish momentum in the MACD and Bollinger Bands.

As of 12 September 2025, the technical trend for Benitec Biopharma, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish trend, while the weekly KST and Dow Theory also reflect a mildly bearish outlook. The MACD shows bullish momentum on the weekly and mildly bullish on the monthly, but this is offset by the bearish signals from the KST and Dow Theory. Bollinger Bands are bullish across both time frames, but the overall sentiment remains cautious due to the daily indicators. There is no available return data to compare the company's performance against the S&P 500.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 363 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.06

stock-summary
Return on Equity

-27.93%

stock-summary
Price to Book

3.72

Revenue and Profits:
Net Sales:
(Quarterly Results - Mar 2025)
Net Profit:
-9 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-5.25%
0%
-5.25%
6 Months
-15.57%
0%
-15.57%
1 Year
31.8%
0%
31.8%
2 Years
309.32%
0%
309.32%
3 Years
6836.84%
0%
6836.84%
4 Years
-73.72%
0%
-73.72%
5 Years
-72.31%
0%
-72.31%

Benitec Biopharma, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Benitec Biopharma, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for Benitec Biopharma, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish trend, while the weekly KST and Dow Theory also reflect a mildly bearish outlook. The MACD shows bullish momentum on the weekly and mildly bullish on the monthly, but this is offset by the bearish signals from the KST and Dow Theory. Bollinger Bands are bullish across both time frames, but the overall sentiment remains cautious due to the daily indicators. There is no available return data to compare the company's performance against the S&P 500....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-220.23%
EBIT to Interest (avg)
-18.55
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.06
Sales to Capital Employed (avg)
0.02
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
94.25%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.30
EV to EBIT
-10.51
EV to EBITDA
-10.64
EV to Capital Employed
-55.27
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-27.93%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 5 Schemes (7.9%)

Foreign Institutions

Held by 7 Foreign Institutions (9.03%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 0.00% vs -100.00% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is -118.60% vs 2.27% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.10",
          "val2": "-4.10",
          "chgp": "-146.34%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.40",
          "val2": "-4.30",
          "chgp": "-118.60%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2024 is -100.00% vs 0.00% in Jun 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2024 is -11.22% vs -7.69% in Jun 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'24",
        "Jun'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-22.30",
          "val2": "-18.70",
          "chgp": "-19.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-21.80",
          "val2": "-19.60",
          "chgp": "-11.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-254,413.30%",
          "chgp": "25,441.33%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Mar'25 - YoYstock-summary
Mar'25
Mar'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-10.10
-4.10
-146.34%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-9.40
-4.30
-118.60%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Mar 2025 is 0.00% vs -100.00% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Mar 2025 is -118.60% vs 2.27% in Mar 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Jun'24stock-summary
Jun'24
Jun'23
Change(%)
Net Sales
0.00
0.10
-100.00%
Operating Profit (PBDIT) excl Other Income
-22.30
-18.70
-19.25%
Interest
0.00
0.00
Exceptional Items
-0.00
-0.00
Consolidate Net Profit
-21.80
-19.60
-11.22%
Operating Profit Margin (Excl OI)
0.00%
-254,413.30%
25,441.33%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Jun 2024 is -100.00% vs 0.00% in Jun 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Jun 2024 is -11.22% vs -7.69% in Jun 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Benitec Biopharma, Inc. stock-summary
stock-summary
Benitec Biopharma, Inc.
Pharmaceuticals & Biotechnology
Benitec Biopharma Inc. formerly Benitec Biopharma Limited, incorporated on April 7, 1995, a is a clinical-stage biotechnology company. The Company focused on the development of genetic medicines. The Company is developing a therapeutic technology platform that combines Ribonucleic acid (RNA) interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. The Company is using this technology, called Deoxyribonucleic acid (DNA)-directed RNA interference, or ddRNAi, to develop product candidates in chronic and life-threatening human disease areas including orphan disease and infectious disease. Benitec endeavors to develop and commercialize BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy, or OPMD. The Company’s pipeline includes Oculopharyngeal Muscular Dystrophy (OPMD) Hepatitis B BB-103.
Company Coordinates stock-summary
Company Details
Level 14, 114 William St , MELBOURNE VIC : 3000
stock-summary
Tel: 61 3 86927222
stock-summary
https://benitec.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."